CAS: 762287-57-0; (4-Chloro-2-Methoxyphenyl)Boronic Acid

该化合物是一种有机体化合物,其特点是,一种附于氯化和甲基氧化苯环的有机体,其特性是含有一种碳酸分酸功能组,该化合物一般是白色的,在白到白的固体中,可溶于甲醇和二甲基硫氧化物等极有机溶剂,众所周知,它能够与二醇形成可逆的共价联系,使其在各种应用中有用,包括有机合成和药用化学.芳香环上存在氯和甲基氧基亚乌拉分解物分体,这可能会影响其再活动性和选择性,例如铃木-米亚乌拉交织等交叉反应.此外,这种氧化物通常用于传感器的开发,以及生物系统研究中,因为它们与生物分子分子相互作用的能力.在处理这一化合物时,应当采取安全防范措施,因为可能对环境产生影响和环境的关切.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号174913-09-8 2-溴-5-氯苯甲醚 | CAS号1377503-12-2 2-羟基-4-氯苯硼酸频哪醇酯

合成工艺路线路线简述

  • 合成目标产物 4-Chloro-2-Methoxyphenylboronic Acid 主要起始原料 2-Bromo-5-Chloroanisole And Trimethyl Borate
  • (文献来源)合成步骤主要原料 2-Bromo-5-Chloroanisole 和 Trimethyl Borate
2-溴-5-氯苯甲醚置于正丁基锂,Triisopropyl Borate,盐酸体系中,用 四氢呋喃,正己烷,水,乙酸乙酯 作为反应溶剂,化学反应 1.0H,反应生成 4-氯-2-甲氧基苯硼酸
参考文献:New 5-Aryl-1H-Imidazoles Display In Vitro Antitumor Activity Against Apoptosis-Resistant Cancer Models,Including Melanomas,Through Mitochondrial Targeting
标题:New 5-Aryl-1H-Imidazoles Display In Vitro Antitumor Activity Against Apoptosis-Resistant Cancer Models,Including Melanomas,Through Mitochondrial Targeting
摘要:We Designed And Synthesized 48 Aryl-1H-Imidazole Derivatives And Investigated Their In Vitro Growth Inhibitory Activity In Cancer Cell Lines Known To Present Various Levels Of Resistance To Proapoptotic Stimuli. The Ic50 In Vitro Growth Inhibitory Concentration Of These Compounds Ranged From >100 Mu M To Single Digit Mu M. Among The Most Active Compounds,2I Displayed Similar In Vitro Growth Inhibition In Cancer Cells Independent Of The Cells' Levels Of Resistance To Proapoptotic Stimuli And Was Found To Be Cytostatic In Melanoma Cell Lines. Compound 2I Was Then Tested By The National Cancer Institute Human Tumor Cell Line Anti-Cancer Drug Screen,And The Nci Compare Algorithm Did Not Reveal Any Correlation Between Its Growth Inhibition Profiles With The Nci Database Compound Profiles. The Use Of Transcriptomically Characterized Melanoma Models Then Enabled Us To Highlight Mitochondrial Targeting By 2I. This Hypothesis Was Further Confirmed By Reactive Oxygen Production Measurement And Oxygen Consumption Analysis.
DOI:10.1021/jm400287V

海关参考信息

专利信息


专利号:US-7968752-B2
优先权日:2003-06-16
标 题:Hydrolytically-resistant boron-containing therapeutics and methods of use
发明人:LEE VING; PLATTNER JACOB J; BENKOVIC STEPHEN J; BAKER STEPHEN J; MAPLES KIRK R; BELLINGER-KAWAHARA CAROLYN; AKAMA TSUTOMU; ZHANG YONG-KANG; SINGH RAJESHWAR; SAURO VITTORIO A
权利人:ANACOR PHARMACEUTICALS INC
摘要:Compositions and methods of use of borole derivatives, including benzoxaboroles, benzazaboroles and benzthiaboroles, as therapeutic agents for treatment of diseases caused by bacteria or viruses are disclosed, as well as methods for synthesis of said agents and compositions thereof.

专利号:US-7645754-B2
优先权日:2001-12-20
标题 :Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use
发明人:CASTELHANO ARLINDO; MCKIBBEN BRYAN; STEINIG ARNO
权利人:OSI PHARM INC
摘要:The subject invention provides compounds having the structure: n n n n n n n n n n n n wherein,n R 1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(â•?O)NR a R b , —NR a R b , —NR a C(â•?O)NR a R b , —NR a C(â•?O)OR a , —OC(â•?O)NR a R b , or —NHC(â•?O) R a ; R 2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(â•?O)NR a R b , —NR a R b , —NR a C(â•?O)NR a R b , —NR a C(â•?O)OR a , —OC(â•?O)NR a R b , or —NHC(â•?O)R a , or R 1 , R 2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH 2 ) 2 OH or —CH 2 C(â•?O)OH; R 3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C 1 -C 15 )alkyl, (C 1 -C 15 )alkoxy, or —NR a R b ; R 4 is hydrogen or substituted or unsubstituted (C 1 -C 15 )alkyl; R 5 is —(CH 2 ) m OR 6 , —CHNOR 7 , —C(â•?O)NR 8 R 9 , —(CH 2 ) m C(â•?O)OR 10 , —(CH 2 ) k C(â•?O)NR 11 R 12 ;n wherein R 6 is a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring; R 7 is hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl; R 8 and R 9 are each independently hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl, (C 1 -C 30 )alkylamino, (C 1 -C 30 )alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, or R 8 , N, and R 9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring; R 10 is hydrogen or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or heterocyclic ring; R 11 , N and R 12 together form a 4-8 membered heterocyclic ring; R a and R b are each independently hydrogen or alkyl; m is 0, 1, 2 or 3; and k is 1, 2 or 3,n nor a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A 2b adenosine receptor in a sbject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.

专利号:US-2025026766-A1
优先权日:2022-01-12
标题 :Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors
发明人:LI JING; XU WENQING; WANG ZHIWEI
权利人:BEIGENE LTD
摘要:The present invention relates to compounds containing thiazolopyridyl amide structure, the process for their synthesis, as well as the use of such compounds for inhibiting DNA Polymerase Theta (Pol Theta), and in the treatment of various diseases including cancers.

专利号:US-9951062-B2
优先权日:2012-12-14
标 题 :Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
发明人:VANKAYALAPATI HARIPRASAD; YERRAMREDDY VENKATAKRISHNAREDDY; GANIPISETTY VENU BABU; TALLURI SURESHKUMAR; APPALANENI RAJENDRA P
权利人:ARRIEN PHARMACEUTICALS LLC
摘要:Compounds according to Formulas I, IA or IB: n nto pharmaceutically acceptable composition, salts thereof, their synthesis and their use as SIK2 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and/or disorders such as cancer, stroke, cardiovascular, obesity and type II diabetes.
邢台奥帆医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.allfinechem.com
企业联系电话:0319-6802888,6808888👤
📞邢台奥帆医药科技有限公司 ⚠️参考联系方式
联系人:王先生
电话:0319-6802888,6808888

传真:0319-6802678
邮箱:sales@allfinechem.com
通信地址: 河北省邢台市内邱县小房岗
邮编: 054200
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:河北省邢台市内邱县小房岗
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
北京普瑞东方化学技术有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.bjpurechem.com
企业联系电话:010-83993285👤
📞北京普瑞东方化学技术有限公司 ⚠️参考联系方式
联系人:冷先生
电话:010-83993285
手机:17610176018
传真:010-63370219
邮箱:sales@bjpurechem.com
通信地址: 北京市海淀区西三环北路50号院6号楼豪柏大厦1708室
邮编: 100048
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:北京市海淀区西三环北路50号院6号楼豪柏大厦1708室
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
濮阳惠成电子材料股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.huichengchem.com
企业联系电话:19638638286👤
📞濮阳惠成电子材料股份有限公司 ⚠️参考联系方式
联系人:张经理
电话:19638638286
手机:19638638286
传真:0393-8961801
邮箱:info@huichengchem.com
通信地址: 河南省濮阳市胜利路西段
邮编: 457001
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:河南省濮阳市胜利路西段
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献

参考DOI号:10.1021/acs.orglett.6b01681
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知